XRAY Director Acquires 2,638 Phantom Stock Shares May 04, 2026

Insider trading activity often signals confidence in a company’s future. When executives and directors acquire shares, it can suggest they believe in the business direction. Today we’re examining a significant insider transaction at XRAY (DENTSPLY SIRONA Inc.), where a director made a notable acquisition. On December 31, 2025, Jonathan Jay Mazelsky, a company director, acquired 2,638 phantom stock units through the directors’ deferred compensation plan. This insider transaction adds to his existing holdings and reflects ongoing confidence in the dental equipment manufacturer’s strategic positioning.

Director Acquires Phantom Stock Through Deferred Compensation

Jonathan Jay Mazelsky, serving as a director at DENTSPLY SIRONA, received an award of phantom stock units on December 31, 2025. This acquisition was processed through the company’s Directors’ Deferred Compensation (DDC) plan, a common structure for board member compensation. The SEC filing disclosed the transaction on January 2, 2026.

Understanding Phantom Stock Awards

Phantom stock represents a contractual right to receive cash or shares equal to the value of company stock at a future date. Directors’ deferred compensation plans allow board members to defer portions of their compensation, often receiving phantom stock units as part of that arrangement. These units track the underlying stock’s performance without requiring immediate share issuance. Mazelsky’s award of 2,638 units increased his total phantom stock holdings to 14,382 units, demonstrating sustained board participation and compensation structure engagement.

Transaction Classification and Reporting

The transaction was classified as an “A-Award,” meaning it represents a grant or award of securities rather than a purchase or sale. Form 4 filings require directors to report all changes in beneficial ownership within two business days of the transaction date. This particular award carried no explicit price per share, as phantom stock awards are typically valued at fair market value on the grant date per company policy and SEC regulations.

What Phantom Stock Means for Insider Confidence

Phantom stock acquisitions differ from direct share purchases but still carry significance for investor analysis. When directors receive and hold phantom stock awards, they maintain economic exposure to company performance. This alignment between director compensation and stock value creates incentive structures that benefit shareholders.

Director Compensation Strategy

DENTSPLY SIRONA uses phantom stock as part of its board compensation framework. This approach allows directors to participate in company value creation without immediate dilution to existing shareholders. The deferred compensation structure also provides tax planning flexibility for board members. Mazelsky’s growing phantom stock position, now at 14,382 units, suggests he views the compensation arrangement favorably and remains committed to the company’s governance.

Market Context for XRAY

DENTSPLY SIRONA operates in the dental equipment and supplies sector, a stable industry with consistent demand. The company maintains a market capitalization of approximately $2.37 billion. Meyka AI rates XRAY a grade of C+, reflecting moderate performance relative to sector peers and broader market conditions. Director acquisitions in this context suggest confidence in management’s strategic direction despite current market positioning.

Insider Trading Activity and Shareholder Implications

This single insider transaction represents a buying signal, though phantom stock awards carry different weight than direct open-market purchases. Director acquisitions through compensation plans indicate ongoing engagement with company strategy and performance metrics. Shareholders should monitor whether additional insider activity follows this award.

Analyzing the Acquisition Pattern

One acquisition with zero dispositions creates a net positive insider activity signal. Mazelsky’s decision to retain and accumulate phantom stock units suggests he expects favorable long-term performance. The absence of any director sales during this period reinforces a constructive outlook. This pattern contrasts sharply with scenarios where insiders simultaneously buy and sell, which can indicate profit-taking or hedging concerns.

What Investors Should Watch

Investors tracking XRAY should note this director activity as one data point among many. Phantom stock awards alone don’t guarantee stock appreciation, but they do reflect management confidence. Future insider filings will reveal whether other executives follow similar patterns. Consistent director acquisitions across multiple quarters would strengthen the bullish signal this transaction provides.

SEC Filing Details and Regulatory Compliance

The transaction received proper regulatory disclosure through SEC Form 4 filing procedures. DENTSPLY SIRONA reported the change in ownership within the required timeframe, demonstrating compliance with securities regulations. All transaction details appear in the official SEC database for public review.

Form 4 Filing Requirements

Form 4 filings require insiders to report beneficial ownership changes within two business days of transaction execution. The filing must include transaction date, security type, quantity, and resulting ownership position. Mazelsky’s filing included all required elements: the December 31, 2025 transaction date, 2,638 phantom stock units acquired, and his new total of 14,382 units. This transparency allows investors to track insider activity in real time.

Accessing Insider Trading Information

All insider transactions are publicly available through the SEC’s EDGAR database. Investors can search by company ticker, insider name, or filing date to track patterns over time. DENTSPLY SIRONA’s insider activity history provides context for evaluating current transactions. Regular monitoring of Form 4 filings helps investors identify trends in executive and director confidence.

Final Thoughts

Jonathan Jay Mazelsky’s acquisition of 2,638 phantom stock units through DENTSPLY SIRONA’s deferred compensation plan signals director confidence in the company’s direction. While phantom stock awards differ from direct share purchases, they demonstrate ongoing commitment to the business and alignment with shareholder interests. The absence of any offsetting sales strengthens the positive signal. Investors should view this transaction as one indicator among many when evaluating XRAY’s prospects. Continued monitoring of insider activity will provide additional insight into management’s confidence levels and strategic outlook for the dental equipment manufacturer.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.